Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Case Reports
. 2018 Mar 31;4(4):298-300.
doi: 10.1016/j.jdcr.2017.09.020. eCollection 2018 May.

Plurifocal cutaneous leishmaniasis during treatment with ustekinumab

Louva Rakotonarivo  1 , Dominique Lons-Danic  1 , Michel Janier  1
Affiliations
Case Reports

Plurifocal cutaneous leishmaniasis during treatment with ustekinumab

Louva Rakotonarivo et al. JAAD Case Rep. .
No abstract available

Keywords: IL, interleukin; PASI, Psoriasis Area Severity Index; TNF, tumor necrosis factor; cutaneous leishmaniasis; psoriasis; ustekinumab.

PubMed Disclaimer

Figures

Fig 1
Fig 1
Initial skin lesions on the right upper limb.
Fig 2
Fig 2
Hematoxylin-eosin stain revealed a dense lymphoplasmacytic infiltrate in superficial and medium dermis, featuring histiocytic granulomas. A high-resolution version of this slide for use with the Virtual Microscope is available as eSlide: VM04518.
Fig 3
Fig 3
Higher magnification Giemsa-stained image displaying numerous histiocyte-macrophages abundantly filled with Leishman bodies. A high-resolution version of this slide for use with the Virtual Microscope is available as eSlide: VM04519.
Fig 4
Fig 4
Involution of lesions of patient with leishmaniasis after treatment with oral miltefosine.
See this image and copyright information in PMC

References

    1. Control of the leishmaniases: report of a meeting of WHO Expert Committee on the control of leishmaniases, Geneva 22-26 March 2010. Vol. 949. WHO Technical Report series; 2011. pp. 1–185.
    1. Buffet P.A., Rosenthal E., Gangneux J.P. Traitement des leishmanioses en France: proposition d'un référentiel consensuel. Presse Med. 2011;40(2):173–184. - PubMed
    1. Leonardi C.L., Kimball A.B., Papp K.A. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) Lancet. 2008;371(9625):1665–1674. - PubMed
    1. Papp K.A., Langley R.G., Lebwohl M. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2) Lancet. 2008;371(9625):1675–1684. - PubMed
    1. Guedes-Barbosa L.S., Pereira da Costa I., Fernandes V., Henrique da Mota L.M., de Menezes I., Scheinberg M.A. Leishmaniasis during anti-tumor necrosis factor therapy: report of 4 cases and review of the literature (additional 28 cases) Semin Arthritis Rheum. 2013;43:152–157. - PubMed

Publication types

LinkOut - more resources